VISEN Pharmaceuticals (FRA:T06) Other Current Assets: €32.26 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T06 VISEN Pharmaceuticals FRA:T06
7 GF Score
Price €2.06
! 5 Warning Signs
View Full Analysis

What is VISEN Pharmaceuticals Other Current Assets?

VISEN Pharmaceuticals FRA:T06 7 Other Current Assets is €32.26 Mil as of Jun. 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

VISEN Pharmaceuticals's other current assets for the quarter that ended in Jun. 2026 was €32.26 Mil.

VISEN Pharmaceuticals's quarterly other current assets increased from Jun. 2025 (€7.35 Mil) to Dec. 2025 (€37.20 Mil) but then declined from Dec. 2025 (€37.20 Mil) to Jun. 2026 (€32.26Mil).

VISEN Pharmaceuticals's annual other current assets declined from Dec. 2023 (€2.86 Mil) to Dec. 2024 (€2.26 Mil) increased from Dec. 2024 (€2.26 Mil) to Dec. 2025 (€37.20 Mil).


VISEN Pharmaceuticals Other Current Assets Related Terms


VISEN Pharmaceuticals Other Current Assets Historical Data

* Premium members only.

The historical data trend for VISEN Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VISEN Pharmaceuticals Other Current Assets Chart

VISEN Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Assets
11.33 2.86 2.26 37.20

VISEN Pharmaceuticals Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Assets Get a 7-Day Free Trial 0.00 2.26 7.35 37.20 32.26
FRA:T06
7GF Score
VISEN Pharmaceuticals FRA:T06
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VISEN Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of €32.26 Mil mean?
VISEN Pharmaceuticals (FRA:T06) has a Other Current Assets of €32.26 Mil as of Jun. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on VISEN Pharmaceuticals.
Is VISEN Pharmaceuticals' Other Current Assets too high?
VISEN Pharmaceuticals' current Other Current Assets is €32.26 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Other Current Assets compare to ZTS?
VISEN Pharmaceuticals' Other Current Assets of €32.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on VISEN Pharmaceuticals. VISEN Pharmaceuticals's current Other Current Assets is €32.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Other Current Assets of €32.26 Mil. The current Other Current Assets is €32.26 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Other Current Assets is €32.26 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VISEN Pharmaceuticals Business Description

Other Exchanges 02561:Hong Kong
Address 69 Jiuzhang Road, Suite 3-108, Floor 3, Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, CHN
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score

Get the complete analysis for FRA:T06

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price